Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of Fluvirin 2009/2010 formulation in adults and elderly subjects
2009-011004-33Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated) in influenza (2 arms), sponsored by Novartis. Primary endpoints: Immunogenicity by haemagglutination inhibition test, Safety of single intramuscular dose and 1 more. Started May 2009; status: completed.
02
Drugs
influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2009-011004-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011004-33.